With reference to the Board meeting notice dated February 02 2021 we hereby inform that the Board of Directors in its meeting held on February 12 2021 has inter-alia approved the Unaudited Financial Results of the Company (Standalone & Consolidated) for the quarter and nine months ended December 31 2020.
In view of the aforesaid we hereby enclose the following:
Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended December 31 2020 along with the Limited Review Report issued by B S R & Co. LLP Statutory Auditors of the Company.
Press Release and Earnings Presentation for the quarter and nine months ended December 31 2020.
Allotted 4 500 Equity Shares of face value of Rs. 2/- at an exercise price of Rs. 60/- per share pursuant to exercise of options under the Employees Stock Option Scheme 2015.
This is for your information and for public at large.
Advanced Enzyme Technologies: Outcome Of Board Meeting
12-Feb-2021
Download PDF
Advanced Enzyme
Informed fund ideas, better judgment. Every month. Mutual Fund Insight, every month since October 2002.
Take charge. Know more. Keep more. Mutual Fund Insight helps you do all three — every month